← Back to Clinical Trials
RecruitingNCT06346600

A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD

Trial Parameters

ConditionNeovascular (Wet) Age-related Macular Degeneration
SponsorSkyline Therapeutics
Study TypeOBSERVATIONAL
PhaseN/A
Enrollment83
SexALL
Min Age50 Years
Max AgeN/A
Start Date2024-04-02
Completion2031-03
Interventions
SKG0106

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This is a Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD). All subject who completed the parent clinical study (NCT06213038 and NCT05986864) will undergo safety and efficacy assessments up to 5 years post study drug injection.

Eligibility Criteria

Inclusion Criteria: Subjects who only meet all of the following criteria are eligible for this study: * nAMD subjects who have been enrolled in the SKG0106-related study and received SKG0106 injection; * Subjects who voluntarily sign an informed consent form (ICF) and comply with the protocol to complete the study Exclusion Criteria: * Subjects who are judged by the investigator unsuitable for this study

Related Trials